Industrialization of exosome manufacturing
Developing a high-performance exosome manufacturing process has been a strategic priority for Codiak since the company’s inception. From the outset, we quickly realized that a commercially scalable, highly efficient and reproducible manufacturing process for this new class of biotherapeutics did not exist – so we built it from the ground up.
Our proprietary manufacturing and analytical technologies are pillar of our engEx™ Platform that we believe will make it possible for us to rapidly turn our engineered exosomes into potent therapeutic candidates with the quality and quantities needed to serve broad patient populations.
Our proprietary manufacturing process is designed to efficiently and reliably produce our exosome therapeutic constructs for multiple clinical targets and/or indications:
Exosomes are engineered utilizing our proprietary scaffold proteins.
Exogenous Drug Loading
If necessary, exosomes are loaded exogenously with a specific therapeutic payload.
Master Cell Banks (MCBs)
Engineered human cell lines that are fully characterized and GMP released.
The cells are cultured at large scale in suspension to produce exosomes, using either fed-batch or continuous (perfusion) technology. We have employed 2,000L fed-batch and 500L perfusion bioreactors. Codiak's novel perfusion technology makes it possible to generate the large volume of exosomes needed for large patient populations.
Exosomes are separated from various types of impurities generated in the bioreactor, yielding product of high purity and quality. Our propriety process is based on advanced chromatography and filtration technology as opposed to the centrifuge-based technology that has been traditionally employed in the field.
Formulation of the purified exosomes in stability-enhancing buffer, followed by filling in vials.
Solving the challenges of bringing a new modality to patients requires consistent diligence and ongoing innovation. We believe our process development team is the best in the industry, keeping us at the forefront of this new field. We continue to refine our manufacturing process and innovate on new methods to push the boundaries on what is possible.
We are also building a new, state-of-the-art clinical manufacturing facility. This facility will enable us to rapidly produce our drug candidates for early clinical testing and, if approved, bring our revolutionary new medicines to patients.